Skip to content

Tiratricol

Tiratricol is a naturally occurring chemical in the body that can also be produced synthetically.

Tiratricolis used as a nutritional supplement for thyroid problems, including thyroid cancer. It is also used to increase the metabolic rate to aid weight loss and to reduce cellulite. However, in many countries, Tiratricol is now considered a potent, unapproved thyroid hormone that can cause serious health problems if used improperly, which is why it can no longer be sold as a dietary supplement.

In France, Tiratricol is sold as a prescription drug for thyroid disorders. Its effects have been the subject of scientific research since the 1950s.

How does Tiratricol work?

Tiratricol works by improving thyroid function. It may also help to lower cholesterol levels and stimulate bone growth.

How effective is Tiratricol?

Tiratricol is likely to be effective in cases of pituitary gland resistance to thyroid hormones.

Tiratricol may be effective when used to treat thyroid cancer in conjunction with the drug levothyroxine, or when used to treat hypothyroidism in young children. Tiratricol is likely to be ineffective when used to support weight loss. Tiratricol is not effective when used to increase metabolic rate to support weight loss in people with normal thyroid function. There is not enough scientific data to make a statement about the effectiveness of Tiratricol when used to reduce cellulite. Further scientific research is needed to evaluate the effectiveness of tiratricol in this application.

Safety and side effects

Tiratricol is safe when used under medical supervision for thyroid problems. It can cause side effects such as severe diarrhea, fatigue, weakness and weight loss. Tiratricol should not be used by people with normal thyroid function.

The use of Tiratricol to treat cellulite and to increase the metabolic rate to support weight loss is not safe or safe.

Precautions and warnings

Pregnancy and lactation: Tiratricol can be used during pregnancy under medical supervision to treat thyroid problems in the developing fetus. However, tiratricol should not be used for other purposes during pregnancy as it could damage the developing baby's heart.

Not enough is known about the safety and harmlessness of Tiratricol during breastfeeding, so breastfeeding women should avoid Tiratricol to be on the safe side.

Elderly people: The use of Tiratricol by elderly people suffering from undiagnosed heart disease might not be safe and harmless.

Heart disease: Taking Tiratricol could worsen symptoms of heart disease.

Chest pain (angina): Taking Tiratricol could make symptoms worse.

High blood pressure: Taking Tiratricol could make existing high blood pressure worse.

Diabetes: There are concerns that tiratricol may interfere with blood sugar control and require adjustment of diabetes medication. For this reason, diabetics should carefully monitor their blood glucose levels while taking tiratricol.

Liver disorders: Tiratricol could damage the liver. It may also aggravate existing liver problems.

Myxedema: Myxedema is a condition caused by an underactive thyroid gland. People suffering from this condition are particularly sensitive to thyroid medications including Tiratricol.

Bleeding problems: Tiratricol may slow down blood clotting. There are concerns that tiratricol may increase the risk of bleeding in people who suffer from certain blood clotting disorders.

Interactions

Tiratricol should not be taken in combination with the following medications

Stimulants

Stimulants accelerate the function of the nervous system. By accelerating the function of the nervous system, stimulants can speed up the heart rate and cause a feeling of restlessness. Taking Tiratricol in combination with stimulants could cause serious side effects including accelerated heart rate and high blood pressure. For this reason, a combination of tiratricol with stimulants should be avoided.

Thyroid hormones

Tiratricol has a similar effect to thyroid hormones. Taking Tiratricol in combination with thyroid hormone preparations could increase the risk of side effects from thyroid hormones.

Care should be taken when combining Tiratricol with the following medications:

Cholestyramine

Cholestyramine may reduce the amount of tiratricol absorbed by the body. As a result, cholestyramine could reduce the effect of tiratricol. To avoid this interaction, tiratricol should be taken at least one hour before or four hours after cholestyramine.

Diabetes medication

Large amounts of tiratricol can lower blood sugar. Diabetes medications are also used to lower blood sugar levels. Taking tiratricol in combination with diabetes medication could result in an excessive drop in blood sugar levels. For this reason, blood glucose levels should be carefully monitored. It is possible that the dosage of diabetes medication may need to be adjusted.

Medication that slows down blood clotting

Tiratricol could slow down blood clotting. Taking Tiratricol in combination with medicines that also slow down blood clotting could increase the risk of bleeding and the tendency to bruise.

Some medications that can slow blood clotting include aspirin, diclofenac (Voltaren), ibuprofen, naproxen, heparin, warfarin and others.

Dosage

The following dosages have been investigated in scientific studies:

Oral

  • For the treatment of thyroid cancer in combination with the drug levothyroxine: 10-24 mcg tiratricol twice daily at the start of treatment. This dosage is gradually increased to the amount needed for optimal effect.

References

  1. Anon. FDA warns against consuming dietary supplements containing tiratricol. FDA. 2000. Available at: www.fda.gov/bbs/topics/ANSWERS/ANS01057.html
  2. Asteria C, Rajanayagam O, Collingwood TN, et al. Prenatal diagnosis of thyroid hormone resistance. J Clin Endocrinol Metab 1999;84:405-10. view abstract.
  3. Beck-Peccoz P, Sartorio A, De Medici C, et al. Dissociated thyromimetic effects of 3, 5, 3'-triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels. J Endocrinol Invest 1988;11:113-8. view abstract.
  4. Bentin J, Desir D, Mockel J. Triac (3,5,3'-triiodothyroacetic acid) induced "pseudohypothyroidism". Acta Clin Belg 1984;39:285-9.
  5. Bracco D, Morin O, Schutz Y, et al. Comparison of the metabolic and endocrine effects of 3,5,3'-triiodothyroacetic acid and thyroxine. J Clin Endocrinol Metab 1993;77:221-8. view abstract.
  6. Chow WS, Lam KS. An overweight woman with galactorrhea. Postgrad Med J 1998;74:121-2.
  7. Dulgeroff AJ, Geffner ME, Koyal SN, et al. Bromocriptine and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 1992;75:1071-5. view abstract.
  8. FDA. FDA warns against consuming triax metabolic accelerator. Available at: www.fda.gov/bbs/topics/ANSWERS/ANS00984.html
  9. FDA. List of orphan designations and approvals. Office of Orphan Products Development. Available at: www.fda.gov/orphan/designat/list.htm.
  10. Ferner RE, Burnett A, Rawlins MD. Triiodothyroacetic acid abuse in a female body builder. Lancet 1986;1:383.
  11. Hawkey CM, Olsen EG, Symons C. Production of cardiac muscle abnormalities in offspring of rats receiving triiodothyroacetic acid (triac) and the effect of beta adrenergic blockade. Cardiovasc Res 1981;15:196-205. view abstract.
  12. Heim J. [Hypothyroidism of central origin corrected by the cessation of Triac therapy]. Ann Med Interne (Paris) 1982;133:588-9. View abstract.
  13. Jaffiol C, Daures JP, Nsakala N, et al [Long term follow up of medical treatment of differentiated thyroid cancer]. Ann Endocrinol (Paris) 1995;56:119-26. view abstract.
  14. Jean-Pastor MJ, Jean P, Biour M, et al [Hepatopathies from treatment with a specialty drug combination of tiratricol-cyclovalone-retinol]. J Toxicol Clin Exp 1986;6:115-21.
  15. Kunitake JM, Hartman N, Henson LC, et al. 3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance. J Clin Endocrinol Metab 1989;69:461-6. View abstract.
  16. Lerman JL, Pitt-rivers R. Physiological activity of triiodo and tetraiodothyroacetic acid on blood-cholesterol levels. Lancet 1956;1:885-9.
  17. Lind P, Langsteger W, Koltringer P, et al. 3,5,3'-Triiodothyroacetic acid (TRIAC) effects on pituitary thyroid regulation and on peripheral tissue parameters. Nuclear Medicine 1989;28:217-20. view abstract.
  18. Lledo Carreres M, Lajo Garrido JL, Gonzalez Rico M, et al. Toxic internuclear ophthalmoplegia related to antiobesity treatment. Ann Pharmacother 1992;26:1457-8.
  19. McDermott MT, Ridgway EC. Central hyperthyroidism. Endocrinol Metab Clin North Am 1998;27:187-203. view abstract.
  20. Mechelany C, Schlumberger M, Challeton C, et al. TRIAC (3,5,3'-triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with L-thyroxine. Clin Endocrinol (Oxf) 1991;35:123-8. view abstract.
  21. Menegay C, Juge C, Burger AG. Pharmacokinetics of 3,5,3'-triiodothyroacetic acid and its effects on serum TSH levels. Acta Endocrinol (Copenh) 1989;121:651-8. view abstract.
  22. Mueller-Gaertner HW, Schneider C. 3,5,3'-Triiodothyroacetic acid minimizes the pituitary thyrotrophin secretion in patients on levo-thyroxine therapy after ablative therapy for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 1988;28:345-51. view abstract.
  23. Nicolini U, Venegoni E, Acaia B, et al. Prenatal treatment of fetal hypothyroidism: is there more than one option? Prenat Diagn 1996;16:443-8. view abstract.
  24. Olsen EG, Symons C, Hawkey C. Effect of triac on the developing heart. Lancet 1977;2:221-3. View abstract.
  25. Pitt-Rivers R. Physiological activity of the acetic acid analogues of some iodinated thyronines. Lancet 1953;2:234.
  26. Radetti G, Persani L, Molinaro G, et al. Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid 1997;7:775-8. view abstract.
  27. Sherman SI, Ladenson PW. Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. J Clin Endocrinol Metab 1992;75:901-5. view abstract.
  28. Sherman SI, Ringel MD, Smith MJ, et al. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 1997;82:2153-8. view abstract.
  29. Takeda T, Suzuki S, Liu RT, et al. Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab 1995;80:2033-40. view abstract